COVID-19

HIV vaccine development harnesses breakthroughs in structure-based antigen design, sequencing, and single-cell analysis to create potent vaccines. Prof. Barney Graham, Professor of Medicine, Microbiology, Chemistry and Immunology, Morehouse School of Medicine in Atlanta, Georgia, USA explores advances reported at CROI 2024, emphasizing advances in targeting antibody lineages and augmenting CD8+ T cell responses, and highlighting sustaining funding models for HIV research and it's imperativeness for addressing broader public health issues.

HIV vaccine development, emphasizing HIV, RSV, and coronavirus COVID-19 research is discussed by Prof. Barney Graham. This information is crucial for immunologists, virologists, and those in vaccine research. Learn from cross-disciplinary strategies. You, as healthcare professionals in these fields, need to grasp these insights for innovation. HIV, RSV, and coronavirus studies offer valuable lessons. Keep up with the latest in vaccine technology.

HIV diagnostic technologies are rapidly advancing, as Dr. Nitika Pai discussed, with self-tests and multiplex testing leading the way in accuracy and accessibility. The challenge remains in cost and strategic deployment. This field interests infectious disease specialists, clinical epidemiologists, and public health professionals. Stay informed on innovations like CRISPR and machine learning to enhance patient care. NAT (Nucleic Acid Test) costs and algorithmic bias in machine learning need attention for equitable access.

HIV diagnostics have transformed post-COVID, enhancing the acceptance and implementation of self-tests globally. Dr Nitika Pai, Division of Clinical Epidemiology, Experimental Medicine, Infectious Disease, McGill University, Montreal, Canada, discusses advancements in HIV diagnostics, especially self-testing, which has increased the acceptance and implementation of HIV self-tests globally.

Molnupiravir, an oral antiviral against SARS-CoV-2 was first granted emergency use authorisation in 2021 to reduce the risk of hospitalisation and death in mild to moderate COVID-19 with increased risk of developing severe disease. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the mechanism of action of […]

PANORAMIC (ISRCTN30448031) was a multicentre, open-label, randomized controlled trial investigating novel treatments for COVID-19 in the UK. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the PANORAMIC study results, and how these insights will optimise the use of molnupiravir in clinical practice. Catch up: Interview with Prof. […]

The COVID-19 pandemic brought about the accelerated development of vaccinations to protect against variants of SARS-CoV-2, recently new targets of broad protection against potential future variants have been outlined and numerous vaccine candidates are in pre-clinical and clinical development. It was a pleasure to speak with Editorial Board member Dr. Christoph Spinner (Technical University of […]

Molnupiravir is an oral antiviral medication that has shown to be effective in treating COVID-19. Nirmatrelvir/ritonavir is a combination of two drugs that have been granted emergency use authorization for the treatment of COVID-19. Dr Jon Salmanton-Garcia (University of Cologne and University Hospital Cologne, Cologne, Germany) discusses an analysis on the effectiveness of molnupiravir compared […]